English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Efonidipine hydrochloride ethanolate (EFE), a dihydropyridine calcium channel blocker, is used for the treatment of hypertension. To find the EFE in pre-clinical samples (rat plasma), an HPLC method was devised for the current experiment. The biological samples were prepared using the methanolic extraction procedure to eliminate solvent effects. Using a C18 column, a pH-adjusted mobile phase of methanol and water (90:10, v/v) at a flow rate of 1 mL/min, and UV detection at 252 nm were utilized for chromatographic separation. The retention time of EFE was found to be 5.2 min. The developed bioanalytical method was validated with different validation parameters. The validation parameter results are within the acceptable range of the International Council for Harmonization guidelines. The method was successfully employed to evaluate the pharmacokinetic properties in Wistar albino rats following a single oral administration of 10 mg/kg of EFE. Therefore, the simple method would make it possible to detect EFE quickly and affordably from biological material.

analytical chemistry letters

Bioanalytical method development and Validation for determination of efonidipine hydrochloride ethanolate in rat plasma by high-performance liquid chromatography: applications for pharmacokinetic study